Micro RNAs to Predict Response to Androgen Deprivation Therapy

Completed

Conditions studied: Prostate Cancer

In brief

Identify exosomal micro RNA that predict responses to ADT

Key facts

Study ID

NCT02366494

Run by

Medical College of Wisconsin

People needed

42

Starts

2015-04-29

Expected to finish

2021-05-11

Last updated by the study team

2024-11-25

Who can join

Age: 21 and older, up to 85. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven prostate cancer.
• Testosterone level >30ng/ml and at least 6 months since last dose of hormonal therapy.
• History/physical examination including a detailed description of the stage of prostate cancer within 8 weeks prior to registration.
• CT scan of abdomen and pelvis with IV contrast and bone scan should be performed within 8 weeks prior to registration.
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
• Age ≥ 18.
• Patients must provide study-specific informed consent prior to study entry for this project and mandatory blood specimen for banking for future studies (future studies may include genetic testing).

You may not qualify if…

• Received hormonal therapy less than 6 months prior to registration.
• History of active secondary malignancy.
• Decline hormone therapy for prostate cancer.
• Current or previous treatment with 5-alpha reductase inhibitors within 6 months prior to enrollment.

Where it is running

• Froedtert Hospital — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.